Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value?

Yahoo FinanceDec 25 06:35 ET

Wells Fargo Downgrades Viridian Therapeutics(VRDN.US) to Hold Rating, Cuts Target Price to $27

Moomoo NewsDec 20 13:31 ET · Ratings

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday

BenzingaDec 19 09:07 ET

Wells Fargo Downgrades Viridian Therapeutics to Equal-Weight, Announces $27 Price Target

BenzingaDec 19 07:34 ET · Ratings

Buy Rating Reaffirmed for Viridian Therapeutics: Promising Phase 3 Results for Veligrotug in TED Treatment

TipRanksDec 18 00:45 ET · Ratings

RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $47

Moomoo NewsDec 17 13:31 ET · Ratings